Adenovirus 

​

Ingredients: 

​

human-diploid fibroblast cell cultures (strain WI-38),  Dulbecco’s Modified Eagle’s Medium, fetal bovine serum, sodium bicarbonate, monosodium glutamate, sucrose, D-mannose, Dfructose, dextrose, human serum albumin, potassium phosphate, plasdone C, anhydrous lactose, microcrystalline cellulose, polacrilin potassium, magnesium stearate, microcrystalline cellulose, magnesium stearate, cellulose acetate phthalate, alcohol, acetone, castor oil, FD&C Yellow #6 aluminum lake dye

​

Mortality/Morbidity:

Severe morbidity and mortality associated with adenovirus infections are rare in immunocompetent hosts. Uncommon complications that increase the risk of mortality include meningoencephalitis and pneumonitis.

Severe adenovirus infections have been reported in immunocompromised patients, such as transplant patients and those with inherited and acquired immunodeficiency states. Mortality rates associated with adenovirus infections among pediatric and adult transplant recipients have varied from 6%-70%.

Morbidity and deaths due to pronounced host inflammatory responses have occurred in past gene vector trials.

As with polio vaccines, live adenovirus vaccines in the 1950s became contaminated with simian virus 40 (SV40), with resulting concern that this virus caused various cancers. After subsequent long-term follow-up, some studies have found a moderate association between SV40 and human cancers as a transforming virus, while some other studies have reported no such findings.